Chunlizhengda Calls 2025 AGM and Seeks Mandate for H-Share Buyback

An update from Beijing Chunlizhengda Medical Instruments Co., Ltd. Class H ( (HK:1858) ) is now available.

Beijing Chunlizhengda Medical Instruments has convened its 2025 annual general meeting for 26 May 2026 in Beijing, where shareholders will review the company’s 2025 operating and financial performance. They will vote on the annual report and financial statements, the profit distribution plan, the independent non-executive directors’ performance report and the board’s work report, as well as set directors’ remuneration and appoint domestic and overseas auditors and an internal control auditor for 2026.

Shareholders will also consider a special resolution to grant the board a general mandate to repurchase up to 10% of the company’s H shares during a specified period. The proposed authorization would allow the board broad discretion to design and implement the buyback, handle regulatory procedures in China and overseas markets, cancel repurchased shares, reduce registered capital and amend the articles of association, potentially giving the company greater flexibility in capital management and signaling confidence in its valuation.

More about Beijing Chunlizhengda Medical Instruments Co., Ltd. Class H

Beijing Chunlizhengda Medical Instruments Co., Ltd. is a PRC-incorporated joint stock company listed in Hong Kong as an H-share issuer. The company operates in the medical instruments sector, focusing on the development, production and sale of medical devices for the Chinese and international healthcare markets.

Average Trading Volume: 723,413

Technical Sentiment Signal: Sell

Current Market Cap: HK$7.71B

For an in-depth examination of 1858 stock, go to TipRanks’ Overview page.